Based on the Ascendis Pharma AS stock forecast from 13 analysts, the average analyst target price for Ascendis Pharma AS is USD 188.59 over the next 12 months. Ascendis Pharma AS’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ascendis Pharma AS is Slightly Bullish , which is based on 5 positive signals and 3 negative signals. At the last closing, Ascendis Pharma AS’s stock price was USD 145.74. Ascendis Pharma AS’s stock price has changed by -6.92% over the past week, +20.58% over the past month and -0.60% over the last year.
No recent analyst target price found for Ascendis Pharma AS
No recent average analyst rating found for Ascendis Pharma AS
Company Overview Ascendis Pharma AS
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Read Less
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and...Read More
Frequently Asked Questions About Ascendis Pharma AS (ASND) Stock
Based on ratings from 13 analysts Ascendis Pharma AS's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 24 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on ASND's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for ASND is USD 188.59 over the next 12 months. The maximum analyst target price is USD 289 while the minimum anlayst target price is USD 153.
ASND stock's Price/Earning ratio is 1.19.
Our analysis grades ASND stock's Price / Earning ratio at D+. This means that ASND stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ASND may be fairly valued for its sector
The last closing price of ASND's stock was USD 145.74.
The most recent market capitalization for ASND is USD 9.37B.
Based on targets from 13 analysts, the average taret price for ASND is projected at USD 188.59 over the next 12 months.
This means that ASND's stock price may go up by +29.40% over the next 12 months.
We can't find any ETFs which contains Ascendis Pharma AS's stock.
As per our most recent records Ascendis Pharma AS has 1,017 Employees.
Ascendis Pharma AS's registered address is Tuborg Boulevard 12, Hellerup, Denmark, 2900.
You can get more information about it from Ascendis Pharma AS's website at https://ascendispharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Ascendis Pharma AS (ASND) Stock
Based on ratings from 13 analysts Ascendis Pharma AS's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 24 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on ASND's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for ASND is USD 188.59 over the next 12 months. The maximum analyst target price is USD 289 while the minimum anlayst target price is USD 153.
ASND stock's Price/Earning ratio is 1.19.
Our analysis grades ASND stock's Price / Earning ratio at D+. This means that ASND stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ASND may be fairly valued for its sector
The last closing price of ASND's stock was USD 145.74.
The most recent market capitalization for ASND is USD 9.37B.
Based on targets from 13 analysts, the average taret price for ASND is projected at USD 188.59 over the next 12 months.
This means that ASND's stock price may go up by +29.40% over the next 12 months.
We can't find any ETFs which contains Ascendis Pharma AS's stock.
As per our most recent records Ascendis Pharma AS has 1,017 Employees.
Ascendis Pharma AS's registered address is Tuborg Boulevard 12, Hellerup, Denmark, 2900.
You can get more information about it from Ascendis Pharma AS's website at https://ascendispharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ASND !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
